RxDoctor Payments Data

Anisha Antony

Family · Chandler, AZNPI 1033995154

Payments from drug & device makers

$3,692in general payments, 2019–2025

Across 194 payments — averaging $19.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$553
  • Gilead$408
  • AstraZeneca$375
  • Lilly USA, LLC$350
  • Bayer$267
  • AbbVie$253
  • plus $1K from 27 others

What the payments were for

  • Food & beverage$3,692100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,692 in reported general payments places this provider in the 90th percentile of 4,119 family providers in Arizona.

See all family providers in Arizona

Medicare billing

Part B allowed, 2024
$17,894
Medicare patients
87
Services billed
1,257

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide33$46,527
JardianceEmpagliflozin19$26,296
OzempicSemaglutide22$23,023
EliquisApixaban14$16,329
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine12$542
Albuterol Sulfate HfaAlbuterol Sulfate25$398
Levothyroxine Sodium35$325
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst19$291
Rosuvastatin Calcium18$275
Atorvastatin Calcium41$272
Tamsulosin Hcl11$271
Losartan Potassium32$252
Azithromycin74$242
Gabapentin13$240
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav27$220

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$350$46,52733 claims
Boehringer IngelheimJardiance$74$26,29619 claims
Novo NordiskOzempic$230$23,02322 claims
PfizerEliquis$67$16,32914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,119 family providers in Arizona.

Other family in Chandler

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →